Chest
Communications to the EditorAllergic Bronchopulmonary Aspergillosis Treated With Itraconazole
Section snippets
To the Editor
The study reported by Drs. Mroueh and Spock1 in the January 1994 issue of Chest emphasizes the efficacy of corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA), an unusual complication of cystic fibrosis. But patients who failed to respond could be treated with itraconazole, an orally administered triazole antifungal agent.
Mannes et al2 recently reported favorable results with itraconazole as adjunctive therapy for ABPA in twins with cystic fibrosis. Using the same drug,
References (5)
- et al.
Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
Chest
(1994) - et al.
Itraconazole and allergic bronchopulmonary aspergillosis in twin brothers with cystic fibrosis
Lancet
(1993)
Cited by (48)
Allergic bronchopulmonary aspergillosis
2009, ChestCitation Excerpt :We use inhaled corticosteroids only for the control of asthma once the oral prednisolone dose is reduced to < 10 mg/day. Ketoconazole has been tried in the past147 and has been replaced by the less toxic agent, itraconazole.130,141,148–160 Only two randomized controlled studies (84 patients) have evaluated the role of itraconazole in ABPA.130,156
Aspergillosis overlap syndrom: Diagnostic and therapeuthic difficulties
2004, Revue des Maladies RespiratoiresAllergic bronchopulmonary aspergillosis
2002, Revue Francaise d'Allergologie et d'Immunologie CliniqueAntifongiques et aspergilloses
2001, Revue Francaise des LaboratoiresDiagnosis and treatment of allergic bronchopulmonary aspergillosis
2001, Mayo Clinic ProceedingsThe role of antifungals in the management of patients with severe asthma
2020, Clinical and Translational Allergy
Communications for this section will be published as space and priorities permit. The comments should not exceed 350 words in length, with a maximum of five references; one figure or table can be printed. Exceptions may occur under particular circumstances. Contributions may include comments on articles published in this periodical, or they may be reports of unique educational character. Specific permission to publish should be cited in a covering letter or appended as a postscript.